DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

01 مايو 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

11 مارس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

25 فبراير 2021 15:01:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

12 فبراير 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

05 فبراير 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

11 يناير 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

08 يناير 2021 07:30:00 بحسب Nasdaq GlobeNewswire